| Bioactivity | EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC50s of 0.4 µM and 1.6 µM for EGFR and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis[1]. |
| Invitro | EGFR-IN-45 (compound 30b) (0-10 μM; 48 hours) exhibits the high anticancer activity against Panc-1, MCF-7, HT-29 and A-549[1].EGFR-IN-45 (20 and 100 μM; hours) can inhibit Topo I and Topo II in a dose-dependent manner[1].EGFR-IN-45 (0-8 μM; 24 hours) has a high percentage of cell accumulation in the pre-G1 phase in MCF-7[1].EGFR-IN-45 (0-8 μM; 24 hours) induces high amounts of apoptosis, with a necrosis percent of 2.99[1]. Cell Proliferation Assay Cell Line: |
| Name | EGFR-IN-45 |
| Formula | C28H23N7O |
| Molar Mass | 473.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |